Hereditary Tyrosinemia Pathogenesis, Screening and Management
-88%
Availability: In Stock

Hereditary Tyrosinemia Pathogenesis, Screening and Management

SKU: 9783319557809

Original price was: $209.00.Current price is: $24.99.

Access Hereditary Tyrosinemia Pathogenesis, Screening and Management Now. Discount up to 90%

Categories: ,

Additional information

Full Title

Hereditary Tyrosinemia Pathogenesis, Screening and Management
Author(s)
Edition
ISBN

9783319557809, 9783319557793
Publisher

Springer
Format

PDF and EPUB

Description

Hereditary tyrosinemia type 1 (HT1), the most severe inborn error of the tyrosine degradation pathway, is due to a deficiency in fumarylacetoacetate hydrolase (FAH). The worldwide frequency of HT1 is one per 100,000 births, but some regions have a significantly higher incidence (1:1,800). The FAH defect results in the accumulation of toxic metabolites, mainly in the liver. If left untreated, HT1 is usually fatal before the age of two. HT1 patients develop several chronic complications including cirrhosis with a high risk of hepatocellular carcinoma (HCC) and neuropsychological impairment. Treatment comprises an inhibitor of the pathway, Nitisinone, a strict dietary treatment or liver transplantation. Early treatment is important to avoid HCC. The book includes the latest developments on the molecular basis of HT1, its pathology, screening and diagnosis and management of the disease written by leading scientists, geneticists, hepatologists and clinicians in the field.

Related products